amyloidosis treatment

FDA Approved AMVUTTRA for hATTR

June 14, 2022

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

AL Amyloidosis vs Multiple Myeloma

October 28, 2021

In reality, while there are ample similarities where some view AL amyloidosis and multiple myeloma as “cousins,” there are important differences.

CRISPR/Cas9 – Editing the Code of Life

March 20, 2021

The scientific world is abuzz … a Nobel Prize-winning technology called CRISPR/Cas9 can now edit our DNA. This programmable gene-editing technology, which is efficient, precise, and scalable, has inspired a gold rush of countless applications in medicine, agriculture and basic science. In this blog we invite you to read more about this ground-breaking advance and how, with one course of treatment, it could potentially cure hereditary transthyretin (hATTR / ATTRv) amyloidosis.

1st FDA-Approved Drug for AL Amyloidosis

January 16, 2021

After decades of relying on treatments approved for other diseases, on January 15, 2021 the FDA approved the first drug for AL Amyloidosis. Truly a game-changing, monumental advancement in the treatment of this disease.

Amyloidosis and Diet

November 10, 2019

While there is no special diet that will cure or treat Amyloidosis, both healthy eating and following doctor-recommended restrictions are essential. Guest blogger Lori Grover offers some tips on dealing with dietary changes.

FDA Approved AMVUTTRA for hATTR

AL Amyloidosis vs Multiple Myeloma

CRISPR/Cas9 – Editing the Code of Life

1st FDA-Approved Drug for AL Amyloidosis

Amyloidosis and Diet

Be A Part Of Our Mission!

You have Successfully Subscribed!